CAR-T细胞疗法如何把患者自身的T细胞改造成能清除CD19阳性B细胞恶性肿瘤的活药?
How does CAR-T therapy turn a patient's own T cells into living drugs that clear CD19-positive B-cell malignancies?
给T细胞装上识别CD19的嵌合抗原受体。采集患者外周血T细胞,用病毒载体转入由CD19单链抗体片段、铰链跨膜区和CD3ζ加4-1BB共刺激域拼成的CAR,体外扩增后回输体内;CAR绕过MHC限制直接结合瘤细胞表面CD19,交联后激活内源性杀伤与增殖程序,持续清除B系肿瘤,代价是常伴发细胞因子释放综合征。
It grafts a CD19-directed chimeric antigen receptor onto T cells. A patient's peripheral blood T cells receive, via viral vector, a CAR built from a CD19 single-chain antibody fragment fused to hinge/transmembrane segments plus CD3-zeta and 4-1BB costimulatory domains, then are expanded ex vivo and reinfused. Binding surface CD19 without MHC restriction triggers native killing and proliferation programs that keep clearing B-lineage tumor, at the frequent price of cytokine release syndrome.
难度 专业 · 适合 初中(12-15)
CC BY 4.0 · 已核验 · Verified 2026-11-02
来源 · Source
Porter DL等论文《Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia》,New England Journal of Medicine 2011(宾夕法尼亚大学June团队)
Porter DL et al., 'Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia', New England Journal of Medicine, 2011 (June lab, University of Pennsylvania)
独立核验依据 · Independent verification: 核验依据 1 EUROPEPMC 标识 21830940：Chimeric antigen receptor-modified
#免疫治疗 #CAR-T #嵌合抗原受体
synNotch受体怎样让T细胞只有在同时看到两种肿瘤抗原时才发动攻击,以免误伤正常组织?
How do synNotch receptors make T cells attack only when two tumor antigens appear together, sparing healthy tissue?
它把识别事件翻译成基因表达,构成与门电路。synNotch受体结合抗原A后,胞内核心经蛋白酶剪切释放入核,开启针对第二种抗原的CAR基因表达;T细胞只有先被抗原A启动、再遭遇抗原B才执行杀伤,仅表达其中任一抗原的健康组织得以幸免。Roybal等验证这套与门逻辑可清除双抗原阳性肿瘤而不伤单阳细胞,为实体瘤免疫治疗提供控制脱靶毒性的通用框架。
It translates recognition events into gene expression, wiring up an AND gate. Once a synNotch receptor binds antigen A, its intracellular core is cleaved, released and enters the nucleus to switch on a CAR directed against a second antigen; the T cell kills only after being primed by antigen A and then meeting antigen B, so tissue expressing either marker alone is left untouched. Roybal and colleagues showed this AND logic clears dual-positive tumors without harming single-positive cells, giving solid-tumor immunotherapy a general blueprint for containing off-target toxicity.
难度 专业 · 适合 高中(15-18)
CC BY 4.0 · 已核验 · Verified 2026-11-02
来源 · Source
Roybal KT等论文《Engineering T cells with customized therapeutic response programs using synthetic Notch receptors》,Cell 2016(加州大学旧金山分校Lim实验室)
Roybal KT et al., 'Engineering T cells with customized therapeutic response programs using synthetic Notch receptors', Cell, 2016 (Lim lab, University of California, San Francisco)
独立核验依据 · Independent verification: 核验依据 1 CROSSREF 标识 10.1016/j.cell.2016.09.011：Engineering T Cel
#合成Notch受体 #逻辑门控 #实体瘤
抗PD-1抗体为什么能治疗黑色素瘤等多种晚期癌症,它解除的是哪条免疫刹车通路?
Why do anti-PD-1 antibodies work against advanced melanoma and many other cancers, and which immune brake do they release?
解除肿瘤经PD-1/PD-L1通路对T细胞的抑制。T细胞被抗原激活后表达受体PD-1,肿瘤细胞则高表达配体PD-L1,两者结合会招募SHP-2磷酸酶削弱TCR与CD28信号,使T细胞耗竭失能;抗体占据PD-1后刹车信号中断,耗竭的T细胞重新增殖并杀伤肿瘤,故对多种实体瘤广谱有效,但过度活化也可能引发免疫相关不良反应。
They cut off the inhibition tumors impose through PD-1/PD-L1 signaling. Antigen-activated T cells display the receptor PD-1 while tumor cells overexpress its ligand PD-L1; engaging the pair recruits SHP-2 phosphatase that weakens TCR and CD28 signals, driving T-cell exhaustion. An antibody occupying PD-1 interrupts this brake, letting exhausted T cells re-expand and kill tumor cells - broad activity across solid cancers, though overactivation can trigger immune-related side effects.
难度 进阶 · 适合 大众
CC BY 4.0 · 已核验 · Verified 2026-11-02
来源 · Source
Topalian SL等论文《Safety, activity, and immune correlates of anti-PD-1 antibody in cancer》,New England Journal of Medicine 2012(约翰斯·霍普金斯大学)
Topalian SL et al., 'Safety, activity, and immune correlates of anti-PD-1 antibody in cancer', New England Journal of Medicine, 2012 (Johns Hopkins University)
独立核验依据 · Independent verification: 核验依据 1 EUROPEPMC 标识 22658127：Safety, activity, and immune corre
#免疫治疗 #PD-1 #免疫检查点
抗CTLA-4抗体伊匹木单抗为什么能唤醒抗癌免疫,它在免疫应答的哪个阶段解除刹车?
Why does the anti-CTLA-4 antibody ipilimumab awaken anticancer immunity, and at which stage of the immune response does it release the brake?
它在T细胞活化最早期松开CTLA-4这把共抑制刹车。初始T细胞被抗原提呈细胞激活时上调CTLA-4,与CD28竞争结合B7分子并传入抑制信号,压制克隆扩增;伊匹木单抗占据CTLA-4后,B7得以持续激活CD28共刺激通路,新效应T细胞大规模增殖并浸润肿瘤。2010年三期临床显示其首次延长转移性黑色素瘤总生存期,但免疫过度激活也可引起结肠炎等不良反应。
It releases the costimulatory brake CTLA-4 at the earliest stage of T-cell activation. Naive T cells raise CTLA-4 upon meeting antigen-presenting cells; competing with CD28 for B7 ligands, CTLA-4 delivers inhibitory signals that curb clonal expansion. Once ipilimumab occupies CTLA-4, B7 keeps engaging CD28, so fresh effector T cells expand massively and infiltrate tumors. The 2010 phase III trial showed the first overall-survival benefit in metastatic melanoma, though runaway immunity can cause colitis-like adverse effects.
难度 入门 · 适合 大众
CC BY 4.0 · 已核验 · Verified 2026-11-02
来源 · Source
Hodi FS等论文《Improved survival with ipilimumab in patients with metastatic melanoma》,New England Journal of Medicine 2010(丹娜-法伯癌症研究所牵头的多中心试验)
Hodi FS et al., 'Improved survival with ipilimumab in patients with metastatic melanoma', New England Journal of Medicine, 2010 (multicenter trial led by Dana-Farber Cancer Institute)
独立核验依据 · Independent verification: 核验依据 1 CROSSREF 标识 10.1056/nejmx100063：Improved Survival with I
#免疫治疗 #CTLA-4 #伊匹木单抗